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Rajani Ravi2, Rannee Mehra4, Mohammad O Hoque2, Ido Sloma5, Daria A Gaykalova2, Antonei B Csoka3, David Sidransky2,
Alex Zhavoronkov1,6,7 and Evgeny Izumchenko2
A subset of patients with oral squamous cell carcinoma (OSCC), the most common subtype of head and neck squamous cell
carcinoma (HNSCC), harbor dysplastic lesions (often visually identiﬁed as leukoplakia) prior to cancer diagnosis. Although evidence
suggest that leukoplakia represents an initial step in the progression to cancer, signaling networks driving this progression are
poorly understood. Here, we applied in silico Pathway Activation Network Decomposition Analysis (iPANDA), a new bioinformatics
software suite for qualitative analysis of intracellular signaling pathway activation using transcriptomic data, to assess a network of
molecular signaling in OSCC and pre-neoplastic oral lesions. In tumor samples, our analysis detected major conserved mitogenic
and survival signaling pathways strongly associated with HNSCC, suggesting that some of the pathways identiﬁed by our algorithm,
but not yet validated as HNSCC related, may be attractive targets for future research. While pathways activation landscape in the
majority of leukoplakias was different from that seen in OSCC, a subset of pre-neoplastic lesions has demonstrated some degree of
similarity to the signaling proﬁle seen in tumors, including dysregulation of the cancer-driving pathways related to survival and
apoptosis. These results suggest that dysregulation of these signaling networks may be the driving force behind the early stages of
OSCC tumorigenesis. While future studies with larger leukoplakia data sets are warranted to further estimate the values of this
approach for capturing signaling features that characterize relevant lesions that actually progress to cancers, our platform proposes
a promising new approach for detecting cancer-promoting pathways and tailoring the right therapy to prevent tumorigenesis.
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INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) is the sixth most
common cancer in the world,1 with an annual incidence of over
50 000 cases in the United States alone.2 Despite improvements in
molecular diagnosis, oral squamous cell carcinoma (OSCC), the
most common subtype of HNSCC, has a poor prognosis with a 5-
year overall survival of ~ 50%,3–5 and no targeted curative
treatments for late-stage OSCC are currently available. As such,
there is a signiﬁcant unmet clinical need for development of novel
targeted approaches against OSCC.
Nearly 20% of patients with OSCC harbor multiple pre-
malignant lesions showing signs of dysplasia, often visually
identiﬁed as leukoplakia.6 As some of these lesions evolve to
malignant neoplasms,6,7 they represent intermediate steps in
OSCC progression.8 It has been postulated, that this multistep
process from normal epithelium to early pre-malignant change to
fully invasive OSCC, involves the accumulation of molecular and
cellular changes.3,9 Indeed, several signaling pathways have been
shown to be dysregulated in OSCC through genetic and
epigenetic alterations such as those involving TP53, PIK3CA,
NOTCH1, SMAD4, CDKN2A, CCND1, FBXW7, HRAS, NRAS and
FAT1.10–16 Although these signaling axes have been implicated
in tumorigenesis, and are correlated with poor patients prognosis,
relatively few molecular changes critical to the progression of oral
leukoplakia to OSCC are currently recognized,17–21 and our
understanding of the complex signaling networks that both
promote OSCC pathogenesis and can be targeted therapeutically
is still limited.
The Gene Expression Omnibus (GEO), the largest public
repository for high-throughput gene expression data, provides
unprecedented opportunities to reveal molecular mechanisms of
cancer. Although multiple efforts taken to identify differentially
expressed genes between OSCC and normal samples have led to
the identiﬁcation of prospective genetic biomarkers and expres-
sion signature patterns,22–27 analyses that rely solely on gene
enrichment statistics fail to capture subtle differences between
samples that arise from dynamic interactions between genes at
the level of signaling networks. The major advantage of pathway-
based methods is their capability to perform biologically relevant
dimensionality reduction as a result of the analysis.28 However,
despite the signiﬁcant advancements in large-scale analytical
methodologies that infer complex transcriptomic changes into the
network of biologically relevant signaling axes,29–33 a systematic
comprehensive analysis of the signaling pathways activation in
OSCC and oral pre-neoplastic lesions has never been done.
We have recently introduced the in silico Pathway Activation
Network Decomposition Analysis (iPANDA) as a scalable robust
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method for quantitative and qualitative large-scale transcriptomic
data analysis.34 The iPANDA method combines pre-calculated
gene co-expression data with gene importance factors based on
the degree of differential gene expression and pathway topology
decomposition for obtaining pathway activation scores. It has
been demonstrated that iPANDA provides signiﬁcant noise
reduction in transcriptomic data and identiﬁes highly robust sets
of biologically relevant pathway signatures.34 In this study, we
applied iPANDA on the transcriptomic data from hundreds of
OSCC and leukoplakia samples to identify the differentially
dysregulated signaling pathways between these neoplasms and
normal oral mucosa tissues. Our work further contributes to the
current understanding of the complex signaling networks under-
lying HNSCC, and may aid in the development of novel means of
prevention, diagnosis and treatment.
RESULTS
iPANDA detects major conserved pathways involved in HNSCC
tumorigenesis
To assess the signaling pathway proﬁle associated with the OSCC
evolution, we ﬁrst performed an in silico pathway activation
analysis of 359 OSCC samples obtained from the publicly available
data sets deposited at NCBI GEO database (GSE41613, GSE42743,
GSE30784 and GSE31056) (Supplementary Table 1). All the data
sets were obtained using the microarray platform Affymetrix
Human Genome U133 Plus 2.0 Array. Human papillomavirus (HPV)
infection does not appear to be a signiﬁcant risk factor for OSCC
and the prevalence of HPV-positive oral cavity cancers is relatively
low, at o6%.35 To avoid the possible noise introduced by
differences in gene expression in HPV-positive and HPV-negative
cancers, all OSCC samples selected for the analysis were HPV
negative. For OSCC cohort used in this study, we have carefully
selected a tissue-speciﬁc normal control cohort (microarrays
derived from non-tumorous oral mucosa of 109 subjects using
the same proﬁling platform as in tumor data set) (Supplementary
Table 2). A collection of 374 intracellular signaling pathways
strongly implicated with various solid malignancies (64 main
signaling pathways and 310 branched axes radiating from the
main pathways) was obtained from the SABiosciences (http://
www.sabiosciences.com/pathwaycentral.php), and used for the
computational algorithm as described previously.28,32–34,36 Using
the normal samples cohort as a reference, we determined a
quantitative measure of the signaling pathway activation scores
(which we refer to as iPANDA values)34 for each one of the
signaling axes analyzed. The iPANDA values represent the signed
scores showing the intensity and direction of the pathway
activation (see Materials and Methods section for details). A total
of 248 of 374 pathways analyzed (including the 64 main
pathways) were signiﬁcantly dysregulated (Po0.05) in OSCC
tumors when these samples were compared with non-tumorous
oral mucosa (Supplementary Table 3). Focusing on the major
pathways involved in cancer development, we have created the
hierarchically clustered heatmap of 64 main pathways differen-
tially activated in 359 OSCC tumors (Figure 1a, Supplementary
Table 4). Upregulated pathways can be seen in red and down-
regulated in blue. As expected, pathways involved in initiation,
progression and maintenance of HNSCC,37,38 such as those
associated with AKT, JNK, IL-6/STAT3, ILK, RAS, MAPK/ERK, p38/
PAK, TGFβ, PI3K/mTOR and WNT signaling, were among the most
signiﬁcantly upregulated molecular axes in OSCC patients
compared to normal controls (Figure 1a). Our pathway activation
prediction analysis further conﬁrms previously reported observa-
tions that despite the remarkable complexity of genomic
alterations in HNSCC, most of them fall within a few major
canonical driver-signaling pathways, and converge the activation
of PI3K/AKT/mTOR, RAS/RAF/MAPK, JAK/STAT, WNT/β-catenin and
TGFβ molecular networks. Activation of these pathways has been
shown to contribute to the malignant growth and metastatic
potential of HNSCC.37–39
Loss of SMAD4 activity via inactivating mutations or loss of
heterozygosity occurs in ~ 50% of patients with HNSCC, and
Smad4 deﬁciency is associated with elevated TGFβ expression and
spontaneous HNSCC formation.15 Whereas activation of PI3K/AKT
via loss of PTEN or copy-number gain/activating mutations in
PIK3CA also occurs in 40–60% of HNSCCs, leading to increased IL-6
production, STAT3 activation and tumor-promoting inﬂammation
in HNSCC stroma.40,41 In concordance with this evidence, PTEN
and SMAD signaling, as well as pathways associated with
apoptosis were signiﬁcantly downregulated in the cohort of 359
OSCC tumors analyzed (Figure 1a).
Analysis of signaling landscape in pre-malignant leukoplakia
lesions
Given the difﬁculties to distinguish pre-neoplastic oral lesions
from cancer, there is an urgent need to elucidate the complexity
of signaling processes underlying the progression from leukopla-
kia to OSCC. Therefore, we next applied iPANDA algorithm to
obtain pathway activation scores based on gene expression
proﬁles of 86 oral pre-neoplastic lesions (GSE26549) (Supplemen-
tary Table 5). Given the difﬁculty of obtaining gene expression
data of well-annotated leukoplakia specimens, this was the only
data set currently available. Since gene expression proﬁles for
these samples were obtained using the later version of the
Affymetrix array (1.0 ST Array), as a reference, we have selected a
cohort of non-tumorous oral mucosa samples proﬁled on the
same platform (GSE38616) (Supplementary Table 6). Out of the
374 pathways analyzed, 210 pathways (64 main pathways and 146
branches) were signiﬁcantly dysregulated (Po0.05) in leukoplakia
samples compared to healthy controls (Supplementary Table 7).
The heatmap for hierarchically clustered 64 main pathways
differentially activated across the 86 leukoplakia samples is shown
in Figure 1b. Interestingly, pathways activation landscape in
leukoplakia was profoundly different from that seen in OSCC. To
better visualize these differences, we have created a super-
imposed bar chart, which depicts the differential expression of 38
main pathways signiﬁcantly dysregulated (Po0.0005) in both
OSCC (red bars) and leukoplakia (blue bars) samples (Figure 1c).
Unlike in OSCC, the average levels of iPANDA values for AKT/
mTOR and other survival and mitogenic pathways, such as ERK,
JNK, RAS/MAPK, p38, PAK, integrin/ILK and TGFβ signaling, were
substantially lower in most leukoplakia samples when compared
to the normal cohort (Figure 1b, Supplementary Table 8). Since
it was postulated that only a subset of pre-malignant oral
lesions may progress to invasive cancer, these data may point
to the possibility that downregulation of molecular pathways
associated with proliferation and survival may direct pre-
neoplastic lesions to spontaneously regress and not to progress
to cancer. Supporting this suggestion, in the majority of the pre-
neoplastic samples, pro-apoptotic pathways were predicted to be
slightly upregulated compared to the normal controls (Figure 1b,
Supplementary Table 8). Notably, similar to OSCC, the SMAD
signaling pathway was also downregulated in leukoplakia. Since
reduced SMAD4 expression may occur in a fairly large percent
(~40%) of oral pre-neoplastic lesions,15,42 our data further support
the role of SMAD4 alterations is an early event in OSCC
tumorigenesis.
Many well-established cancer-driving genes simultaneously
modulate activation or repression of multifunctional signaling
networks that control cell growth, differentiation and migration.
Since ‘main’ pathways aggregate branches that may be inversely
activated, analysis of the pathway branches (which represent
linearized fragments of the main pathway networks with multiple
downstream targets) may help to scale down the complexity of
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Figure 1. Pathway activation analysis in OSCC and oral dysplastic lesions. (a) Transcriptomes from 359 OSCC samples were processed and
analyzed using the iPANDA software suite. Transcriptomic data derived from non-tumorous oral mucosa of 109 subjects was used as a
reference for analysis. The hierarchically clustered heatmap depicts 64 main signaling pathways dysregulated in OSCC samples.
Downregulated iPANDA values for each sample/pathway are indicated in blue, whilst upregulated values are shaded in red. (b) Hierarchically
clustered heatmap represents 64 main differentially activated pathways in 86 oral dysplasia samples. Transcriptomic data from healthy oral
mucosa processes on the same platform was used as a reference. Red boxes represent pathway upregulation and blue boxes represent
pathway downregulation. (c) Superimposed bar chart depicts the differential expression of 38 main pathways signiﬁcantly dysregulated
(Po0.0005) in both OSCC (red bars) and leukoplakia (blue bars) samples.
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common non-linear topology34,43 and potentially unravel the
most critical branches associated with cancer progression. A list of
pathway branches predicted to be signiﬁcantly dysregulated
(Po0.0005) in both OSCC and leukoplakia samples is shown in
Supplementary Table 9. Notably, several sub-branches of ILK,
IGF1R, HIF1, HGF, MAPK and WNT pathways were among the most
differentially dysregulated axes between OSCC and leukoplakia
(Supplementary Table 9), suggesting their role in the transition
from non-invasive to invasive disease. Although analysis of the
distinct linear elements within a large multifunctional cancer
driver network may provide a more comprehensive signaling
signature of the phenotype under investigation, the true value of
these subaxes in HNSCC is a subject of future investigation.
Possible harbingers of malignant transition
To further explore pathways activated in OSCC and leukoplakia,
we have created the hierarchically clustered heatmap of
differentially activated pathways in all samples analyzed
(Figure 2). Although gene expression for OSCC and leukoplakia
tissues have been generated using different versions of the
Affymetrix proﬁling platforms, both arrays showed high degree of
correspondence.44 To adjust for the possible batch effect and
other variations that may arise during the microarray processing,
we have employed cross-platform normalization and ﬁltering
procedures as previously described45 (see Materials and Methods
section for details). While most of the leukoplakia samples
clustered together according to their pathway activation land-
scape, a subset of 20 pre-neoplastic lesions has clustered toward
the center of the heatmap, demonstrating some degree of
similarity to the pathway activation proﬁle seen in OSCC (Figure 2,
Supplementary Table 10). Similar to OSCC, most of these samples
have demonstrated a dramatic upregulation in MAPK, ERK, JNK,
IL-6/STAT3, WNT, TGFβ and glucocorticoid receptor signaling,
suggesting that at least in some cases, dysregulation of these
signaling networks may be the driving force behind the early
stages of OSCC tumorigenesis.
Thirty ﬁve of the 86 leukoplakia patients have developed oral
cancer over the median of 6.08 years follow-up time post
resection of the dysplastic lesion.22 Interestingly, only 7 of the
20 leukoplakia patients whose signaling proﬁles cluster together
with tumor signaling proﬁles have developed an overt neoplasm
during the follow-up period. Since benign oral lesions may exist
for many years without progression to malignancy, a longer
follow-up time may be necessary to further unmask the role of
these pathways in early OSCC development. These data also
indicate that only a fraction of leukoplakias that eventually
progress to malignancy gain aberrations in well-established
cancer-driving pathways, suggesting that HNSCC may arise from
alterations of different molecular pathways and that there is no
single predominant signaling pattern of OSCC progression.
Using the transcriptomic data from the same 86 leukoplakia
samples and multiple independent OSCC data sets, Mao and
colleagues proposed a 29-trancript prediction model of oral
cancer progression (with 8% predicting error rate), indicating that
gene expression levels can be effectively used for phenotype
prediction.22 However, we could not statistically signiﬁcant stratify
patients with leukoplakia according to their progression status
based on the pathway activation proﬁles (not shown), indicating
that predisposition for leukoplakia progression may not have
signiﬁcant manifestation on the functional (pathway) level. One
possible explanation is that the most differentially expressed
genes in a given signature may not be part of the pathways that
actually drive tumor behavior. Alternatively, expression of some
genes within the cancer-driving pathways is not always predictive
of the overall pathway activation. While iPANDA may be a useful
tool when used as input for machine learning algorithms to make
better prediction models,34 we were unable to use modern
machine learning methods, since currently available data to
system dimensionality ratio precludes the development of a
strong classiﬁer at the pathway level. As comprehensive analysis
of the tumor pathway activation proﬁle may provide broader
clinical utility than raw gene expression evaluation, it would be of
paramount importance to reanalyze the data upon accumulation
of additional leukoplakia data sets, and further estimate the values
-40 -20 20 400
Figure 2. A subset of pre-neoplastic lesions cluster with OSCC at the pathway level. To directly compare pathways activated in OSCC and pre-
neoplastic lesions, we have created the hierarchically clustered heatmap of differentially activated pathways in all data sets analyses. Cross-
platform normalization and ﬁltering procedures have employed to adjust for the possible batch effect and other variations that may arise
during the microarray processing. Red boxes represent pathway upregulation and blue boxes represent pathway downregulation.
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of this approach for capturing signaling features that characterize
relevant lesions that actually progress to cancers.
DISCUSSION
An understanding of the protein signaling dynamics during the
HNSCC progression is of critical importance for the development
of new therapeutic approaches and identiﬁcation of novel
prognostic biomarkers. Signaling pathway activation analysis is a
powerful tool for extracting biologically relevant features from
large-scale transcriptomic data. While systematic application of
such approach may contribute to better understanding of
complex signaling networks in various types of cancer, many
popular pathway-based methods29–33 often fail to provide stable
pathway signatures of a speciﬁc phenotype. iPANDA, a recently
reported method for biologically relevant dimensionality reduc-
tion in transcriptomic data, demonstrates better performance for
the noise reduction test in comparison to other pathway analysis
approaches, and produces highly consistent sets of biologically
relevant pathway perturbation signatures on multiple transcrip-
tomic data sets.34 Here, we applied this novel bioinformatics
prediction algorithm on transcriptomic data from 359 OSCC and
86 oral pre-neoplastic samples.
By utilizing our approach, we were able to detect dysregulation
of the major molecular processes involved in HNSCC tumorigen-
esis (such as those involving PI3K/AKT/mTOR, RAS/RAF/MAPK,
JAK/STAT, WNT/β-catenin and TGFβ/SMAD signaling) in almost
every OSCC tumor analyzed. Conﬁrming the emerging view that
while the speciﬁc molecules altered in each individual tumor may
be distinct, they all participate in a handful of dysregulated
molecular pathways that are likely shared among most HNSCC
lesions. Although the association of the above signaling pathways
with HNSCC is not novel, the ability of the gene aggregation
algorithm to identify highly robust sets of pathway signatures
relevant to the HNSCC tumorigenesis, suggests that our platform
provides a rational biomathematical framework for studying
signaling alterations driving the tumorigenic processes, and
further supports the credibility of the pathway activation analysis
as a promising analytical approach.34 It also suggests that some of
the most dysregulated pathway branches identiﬁed by our
algorithm but not yet wet-lab validated as HNSCC related, may
provide an attractive target for future research.
OSCC has been associated with the presence of pre-cancerous
dysplastic lesions, thus providing a rational model to elucidate the
carcinogenic signaling axes in more detail. In contrast to OSCC, we
predicted that survival and mitogenic signaling axes were
downregulated and pathways related to apoptosis were slightly
upregulated in the majority of leukoplakia samples tested. While it
is known that leukoplakia may persist for years without
progression to cancer or undergo spontaneous regression or
disappearance, there is only limited information on the rate and
factors inﬂuencing these processes.46,47 It is possible, that early
lesions demonstrating such signaling phenotype remain stable,
unless they acquire oncogenic mutations in pathways shown to
be dysregulated in OSCC. On the other hand, since only 7 of the
35 pre-neoplastic lesions resected from patients that eventually
developed OSCC have demonstrated tumor-like pathways activa-
tion landscape, it is plausible that in some cases pre-malignant
lesions and OSCCs are not clonally related to each other, and
represent independent neoplastic foci. While the genetic relation-
ship between dysplasia and the associated carcinoma is not yet
deﬁned, it is possible that these observations result due to the
multifocality of the carcinogenetic process, suggesting a ﬁeld
cancerization state in oral cancer development.48
Interestingly, while gene set enrichment (GSEA) analysis of the
same microarray data set with GSEA algorithm detected that gene
sets related with proteasome machinery, MYC upregulation and
ribosomes components were associated with a high risk of oral
cancer development,22 we were unable to stratify patients with
leukoplakia according to their progression status based on our
analysis. Although direct comparison of the data generated by
different computational pathway scoring platforms should be
addressed with caution, GSEA algorithm (and its extensions) relies
solely on gene enrichment statistics, treating pathways as
unstructured sets of genes.29 Whereas our method estimates the
topological coefﬁcients for each gene module as a whole, rather
than for individual genes inside the module, and therefore
outperforms ssGSEA in respect to ranking of the putatively
relevant pathways (described in details here).34
Although this study focused on fundamental signaling pro-
cesses involved in the development of OSCC, branched axes
radiating from these main tumor-driving pathways may provide
safer and more efﬁcient targets for therapeutic intervention than a
pan-pathway blockade. Since most of the existing pathways
collections are being developed and cataloged within individual
research groups, both in industry and in academia, inconsistency
in pathway names annotations and number of pathway compo-
nents (branches) poses a major challenge associated with
prediction modeling of subnetworks within a large cancer driver
superpathway. Therefore, systematic standardization and optimi-
zation of existing signaling pathways databases (such as UniProt,
HPRD, QIAGEN SABiosciences, WikiPathways, Ariadne Pathway
Studio, SPIKE, Reactome, KEGG and others) will eventually
contribute to better resolution of the signaling landscape, and
enhance the development of novel prognostic biomarkers for risk
assessment and treatment interventions at various stages of
cancer progression.
In conclusion, our work poses pathway-based expression data
analysis as a promising hypothesis-generating approach for
detecting cancer-promoting pathways at different stages of
tumorigenesis. However, due to the limited number of currently
available leukoplakia data sets, we could not dissect the molecular
pathways predictive of progression from pre-neoplasia to
carcinoma. As more data sets will become available, transcrip-
tomic analysis of longitudinally collected leukoplakias and tumors
that developed in the same patient over time may allow better
detection of early drivers of OSCC carcinogenesis on the
pathway level.
MATERIALS AND METHODS
Source data sets
For this study, we utilized microarray gene expression data obtained from
NCBI GEO database. OSCC samples and tissue-speciﬁc normal controls used
as a reference are listed in Supplementary Table 1 and Supplementary Table 2,
respectively. Oral dysplastic cohort and non-tumorous oral mucosa
samples proﬁled on the same platform are summarized in Supplemen-
tary Table 5 and Supplementary Table 6, respectively.
Bioinformatics analysis and transcriptomic expression data
pre-processing
OSCC and leukoplakia data with corresponding normal samples were
processed using AFFY (version 1.46.1) and FRMA (version 1.20.0) algorithms
from Bioconductor (www.bioconductor.org). Microarray raw data were
background-adjusted and quantile-normalized using the corresponding R
packages (R Core Team, Vienna, Austria). Obtained gene expression values
were averaged across all replicates. Heatmap generation and hierarchical
clustering were performed using R package gplots. Statistical tests and
correlation analysis were done with the MS Excel software (Microsoft
Corporation, Redmond, WA, USA).
Signaling pathway analysis
Pre-processed gene expression data were loaded into pathway analysis
software, a proprietary suite developed by Insilico Medicine, Inc. that
represents an implementation of the iPANDA algorithm,34 optimized for
cancer studies. Brieﬂy, the database (collection of signaling pathways most
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strongly associated with various types of malignant transformation in
human cells obtained from the SABiosciences collection (http://www.
sabiosciences.com/pathwaycentral.php)) contains a set of 374 signaling
pathways that cover a total of 2294 unique genes. Main pathways
represent complex signaling networks with multiple downstream targets.
Whereas branching axes represent dissected linear signal transduction
units of a large multifunctional pathway. Each pathway contains an
explicitly deﬁned topology represented as a directed graph. Each node
corresponds to a gene or a set of genes, while edges describe biochemical
interactions between genes in nodes and/or their products. All interactions
are classiﬁed as activation or inhibition of downstream nodes. The pathway
size ranges from about 20 to over 600 genes in a single pathway. The
algorithm accounts for the gene grouping into modules based on the
precalculated gene co-expression data (using information from COEX-
PRESSdb database). Each gene module represents a set of genes that
experience signiﬁcant coordination in their expression levels and/or are
regulated by the same expression factors. As described,37 it enables
calculation of the iPANDA pathway activation scores, a value that serves as
a quantitative measure of differential pathway activation between the two
states. Pathway scoring is based on the expression level and the role of a
particular gene in proprietary maps of 300 of signaling pathways. For
estimation of pathway activation, we apply the following rule pathways
with positive iPANDA values that are considered upregulated, while
negative iPANDA values correspond to downregulated pathways.
Cross-platform normalization
To perform cross-platform normalization between Affymetrix U133 Plus 2.0
Array and Affymetrix 1.0 ST Array, we utilized XPN algorithm45 (R package,
CONOR).
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